Share this entry
PD-1 inhibitor cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)
By: News Feed | Last updated: 3rd October 2018 | In: ImmunoOncology, Immunotherapy, Melanoma & Skin Cancer, Oncology, US FDA Onc\Haem Approvals
cemiplimab, CSCC, FDA, Libtayo, PD-1, Regeneron, REGN2810, squamous cell skin cancer
On September 28, 2018, the FDA approved programmed death 1 (PD-1) immune-checkpoint inhibitor cemiplimab-rwlc (Libtayo®, Regeneron) for use in patients with metastatic cutaneous squamous cell carcinoma (CSCC) and patients with locally advanced CSCC unamenable for curative surgery or curative radiation.
Studies R2810-ONC-1423 and R2810-ONC-1540
The first study was an open-label, multicentre, dose-finding study (R2810-ONC-1423, NCT02383212) with expansion cohorts which investigated cemiplimab-rwlc in patients with various advanced solid tumours.
The second study was an open-label, multi-centre, non-randomised, multicohort study (R2810-ONC-1540, NCT02760498) which investigated cemiplimab-rwlc metastatic or locally advanced CSCC patients unamenable for surgery or radiation and regardless of prior therapies received.
The ORR (by RECIST 1.1) for patients with metastatic CSCC was assessed by an independent review committee (IRC). Patients with locally advanced CSCC underwent a composite response assessment of clinical response criteria by digital photography and RECIST 1.1.
The two studies included 108 patients with advanced CSCC, including 75 (69%) with metastatic CSCC and 33 (31%) with locally advanced CSCC. The ORR by IRC was 47% (95% CI, 38-57), made up of 4% complete responses (CR) and 44% partial responses (PR).
The ORR for patients with metastatic CSCC was 47% (95% CI, 35-59) and 49% (95% CI, 31-67) for those with locally advanced disease. At the time of data cut-off, the median response duration was not yet reached (range: 1.0 to 15.2+ months), with 61% of the responses lasting six months or longer. The ORR and durability results were consistent across CSCC subtypes. In patients with locally advanced CSCC, clinical observations as per photographic data matched the radiographic responses.
The safety data included 534 patients treated in both cemiplimab-rwlc trials. Serious adverse reactions included immune-related adverse events (irAEs) such as pneumonitis, hepatitis, colitis, adrenal insufficiency, hypo- and hyperthyroidism, diabetes mellitus and nephritis as well as infusion reactions. Common adverse reactions were fatigue, rash and diarrhoea.
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.